HomeNewsBusinessEconomyIndia's fiscal deficit widens, slowing government expenditure remains a concern

India's fiscal deficit widens, slowing government expenditure remains a concern

While the Centre has increased its capital and revenue spending commitments as part of the Aatmanirbhar Bharat and Gareeb Kalyan announcements, it is clear that some expenditure rationalization is taking place as well.

December 31, 2020 / 18:57 IST
Story continues below Advertisement
Total expenditure for the first eight months of the current fiscal year was Rs 19.06 lakh crore or 62 percent of the budget size of Rs 30 lakh crore
Total expenditure for the first eight months of the current fiscal year was Rs 19.06 lakh crore or 62 percent of the budget size of Rs 30 lakh crore

The Centre’s fiscal deficit for April-November 2020 soared to Rs 10.76 lakh crore, or 135 percent of the full year budgeted target of Rs 7.96 lakh crore, as the government’s finances continued to be stretched due to lower revenues arising from the COVID-19 pandemic and the economic slowdown.

What is noticeable, however, is that while expenditure in November shot up to be the highest in five months, overall consolidated spending levels are much below what analysts expect in a year when there has been clamour for increased public spending.

Story continues below Advertisement

Total expenditure for the first eight months of the current fiscal year was Rs 19.06 lakh crore or 62 percent of the budget size of Rs 30 lakh crore. This compares to 65.3 percent for the same period last year, when total expenditure for April-November 2019 was Rs 18.20 lakh crore versus a budget size of Rs 27.9 lakh crore.

While the Centre has increased its capital and revenue spending commitments as part of the Aatmanirbhar Bharat and Gareeb Kalyan announcements, it is clear that some expenditure rationalization is taking place as well.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show